A TiO2 Nanoparticle System for Sacrificial Solar H2 Production Prepared by Rational Combination of a Hydrogenase with a Ruthenium Photosensitizer

Enterobacter aerogenes AY-2 mutant is known for hydrogen gas producer which ws obtained from the sludge of methane fermentation and the yield is 1.5 fold higher than wildtype. Hydrogen gas production can be gain via NADH oxidation in anaerobic metabolic pathway by blocking organic acid production. Metabolic pathway can be changed by mutagenesis. Enterobacter aerogenes AY-2 mutated with ethyl methane sulfonate in logarithmic phase with consentration 10, 11, 12, 13, 14 and 15 μl/ml cell suspention during 120 minute. Mutation that result lowest survival ratio (0,01%) was 14 μl EMS/ml cell suspention is repeated with variation incubation time, 30, 60, 90 and 120 minute. 166 double mutant colony has been collected and choosen randomly. The choosen 43 colony was fermented in glycerol complex medium for determining ten double mutant with the highest H2 production. Double mutant AD-H43 is a highest H2 producer that increase 20% H2 production from AY-2 and has a decrease lactid acid production, 31% less from AY-2. Increasing H2 production in double mutant AD-H43 is caused by lactate dehydrogenase deffi cient.Keywords: Enterobacter aerogenes AY-2, ethyl methane sulfonate (EMS), H2 and methane sludge

Download Full-text

Faculty Opinions recommendation of Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718380107.793496439 ◽

2014 ◽

Author(s):

Ram Samudrala ◽

Geetika Sethi

Keyword(s):

Lung Cancer ◽

Cancer Resistance ◽

Rational Combination ◽

Egfr Mutant

Download Full-text

Anticancer Agents Based on Vulnerable Components in a Signalling Pathway

Mini-Reviews in Medicinal Chemistry ◽

10.2174/1389557520666200212105417 ◽

2020 ◽

Vol 20 (10) ◽

pp. 886-907 ◽

Cited By ~ 4

Author(s):

Ankur Vaidya ◽

Shweta Jain ◽

Sanjeev Sahu ◽

Pankaj Kumar Jain ◽

Kamla Pathak ◽

...

Keyword(s):

Anticancer Agents ◽

Dna Methyltransferase ◽

Leucine Zipper ◽

Molecular Mechanisms ◽

Resistance Mechanisms ◽

Sphingosine Kinase 2 ◽

Family Protein ◽

Rational Combination ◽

Protein Kinase Akt ◽

Parp 1

Traditional cancer treatment includes surgery, chemotherapy, radiotherapy and immunotherapy that are clinically beneficial, but are associated with drawbacks such as drug resistance and side effects. In quest for better treatment, many new molecular targets have been introduced in the last few decades. Finding new molecular mechanisms encourages researchers to discover new anticancer agents. Exploring the mechanism of action also facilitates anticipation of potential resistance mechanisms and optimization of rational combination therapies. The write up describes the leading molecular mechanisms for cancer therapy, including mTOR, tyrosine Wee1 kinase (WEE1), Janus kinases, PI3K/mTOR signaling pathway, serine/threonine protein kinase AKT, checkpoint kinase 1 (Chk1), maternal embryonic leucine-zipper kinase (MELK), DNA methyltransferase I (DNMT1), poly (ADP-ribose) polymerase (PARP)-1/-2, sphingosine kinase-2 (SK2), pan-FGFR, inhibitor of apoptosis (IAP), murine double minute 2 (MDM2), Bcl-2 family protein and reactive oxygen species 1 (ROS1). Additionally, the manuscript reviews the anticancer drugs currently under clinical trials.

Download Full-text